Mommox Rino (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mommox Rino, is a corticosteroid presented as a nasal spray for intranasal use. It is indicated for the management of allergic rhinitis and nasal polyps, reducing inflammation in the nasal mucosa of adults and children when prescribed by a healthcare professional.

GNH USA supplies Mommox Rino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is available for export to multiple regions globally.

Mommox Rino (mometasone furoate) is a nasal corticosteroid used to treat inflammatory conditions of the nasal passages. - Allergic rhinitis: Reduces nasal inflammation and improves symptoms such as sneezing, itching and congestion. - Nasal polyps: Decreases polyp size and alleviates associated blockage. - Seasonal allergic rhinitis: Controls episodic inflammation triggered by pollen or other seasonal allergens.

Mommox Rino may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleed). - Unpleasant taste or oral dryness.

Serious or Rare Side Effects: - Nasal septal perforation. - Vision changes or cataract formation. - Severe allergic reaction (anaphylaxis).

Before using Mommox Rino, consider the following precautions. - Use only as prescribed: Follow the dosing schedule provided by the prescriber. - Avoid prolonged use: Limit treatment duration unless advised by a physician. - Do not share: The product is for individual use only. - Monitor for infection: Discontinue if signs of fungal or bacterial infection appear in the nose. - Store at room temperature: Keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Mommox Rino may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: May increase systemic exposure of mometasone. - Systemic corticosteroids: Additive immunosuppression risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles: Potentially raise glucocorticoid levels. - Protease inhibitors (e.g., ritonavir): May increase drug concentration. - Live vaccines: May reduce vaccine efficacy.